| Ytd | -67.35% | |
| 1y | -80.44% |
| Open | 0.42 | Prev Close | 0.43 | Low | 0.42 | High | 0.44 | Mkt Cap | 80.33M |
| Vol | 3.77M | Avg Vol | 3.18M | EPS | -0.18 | P/E | N/A | Forward P/E | 178.00 |
| Beta | 1.81 | Short Ratio | 14.20 | Inst. Own | 81.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-07 | 50-d Avg | 0.77 | 200-d Avg | 1.07 | 1yr Est | 6.00 |
Top Wall Street analysts changed outlook on top names. For all rating changes, upgrades and downgrad
HC Wainwright & Co. analyst Brandon Folkes maintains Heron Therapeutics (NASDAQ:HRTX) with a
Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stag